Bausch + Lomb (BLCO) to Release Quarterly Earnings on Wednesday

Bausch + Lomb (NYSE:BLCO) is anticipated to announce its earnings results before the market opens on Wednesday, February 19th. Analysts expect the company to announce earnings of $0.23 per share and revenue of $1.26 billion for the quarter. Persons interested in participating in the company’s earnings conference call can do so using this link.

Bausch + Lomb Price Performance

Bausch + Lomb stock opened at $16.12 on Wednesday. The firm has a market cap of $5.68 billion, a PE ratio of -15.35, a price-to-earnings-growth ratio of 2.13 and a beta of 0.46. The company’s 50 day moving average is $17.87 and its two-hundred day moving average is $18.17. Bausch + Lomb has a 52-week low of $13.16 and a 52-week high of $21.69. The company has a quick ratio of 0.95, a current ratio of 1.57 and a debt-to-equity ratio of 0.69.

Analysts Set New Price Targets

Several brokerages have recently weighed in on BLCO. Citigroup downgraded shares of Bausch + Lomb from a “buy” rating to a “neutral” rating and reduced their price objective for the stock from $24.00 to $22.00 in a research report on Wednesday, December 11th. Evercore ISI upgraded shares of Bausch + Lomb from an “in-line” rating to an “outperform” rating and lifted their price objective for the company from $19.00 to $25.00 in a research report on Tuesday, October 15th. Morgan Stanley cut Bausch + Lomb from an “overweight” rating to an “equal weight” rating and set a $19.00 target price on the stock. in a research report on Monday, December 2nd. Stifel Nicolaus reduced their price objective on shares of Bausch + Lomb from $19.00 to $18.00 and set a “hold” rating for the company in a research note on Wednesday, January 29th. Finally, Needham & Company LLC reissued a “hold” rating on shares of Bausch + Lomb in a report on Thursday, October 31st. One investment analyst has rated the stock with a sell rating, seven have issued a hold rating and five have issued a buy rating to the company’s stock. Based on data from MarketBeat, Bausch + Lomb has a consensus rating of “Hold” and an average target price of $20.25.

Bausch + Lomb Company Profile

Bausch + Lomb Corporation operates as an eye health company in the United States, Puerto Rico, China, France, Japan, Germany, the United Kingdom, Canada, Russia, Spain, Italy, Mexico, Poland, South Korea, and internationally. It operates in three segments: Vision Care, Pharmaceuticals, and Surgical. The Vision Care segment provides contact lens that covers the spectrum of wearing modalities, including daily disposable and frequently replaced contact lenses; and contact lens care products comprising over-the-counter eye drops, eye vitamins, and mineral supplements that address various conditions, such as eye allergies, conjunctivitis, dry eye, and redness relief.